NASDAQ · Financial Statements

Kalaris Therapeutics, Inc. (KLRS) Financial Statements

$1.91 NASDAQ: KLRS Market Cap $41.71M

Kalaris Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $43.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-170.0M$-14.0M$-13.0M$-55.0M$-46.0M
Net Profit$-172.0M$-15.0M$-15.0M$-59.0M$-43.0M
EPS$-63.00$-50.62$-42.09$-11.73$-2.85
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$287.0M$4.0M$3.0M$119.0M$122.0M
Total Liabilities$61.0M$34.0M$48.0M$5.0M$43.0M
Cash$202.0M$3.0M$3.0M$118.0M$98.0M
Borrowings$30.0M$3.0M$0$0$1.0M

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-106.0M$-10.0M$-14.0M$-68.0M$-43.0M
Investing Cash Flow$186.0M$0$0$95.0M$-20.0M
Financing Cash Flow$0$0$2.0M$0$102.0M
Net Cash Flow$79.0M$3.0M$0$28.0M$-20.0M
Free Cash Flow$-106.0M$-10.0M$-14.0M$-68.0M$-43.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-0.42
FCF Yield-74.93%
Quick Ratio10.98
Interest Coverage-46.00
Return 1Y94.58%
Return 3Y-94.20%
Return 5Y-98.85%

Kalaris Therapeutics, Inc. (KLRS) financials — frequently asked questions

What is Kalaris Therapeutics, Inc.'s annual revenue?

Kalaris Therapeutics, Inc. (KLRS) reported annual revenue of $0 in its most recent fiscal year.

What is Kalaris Therapeutics, Inc.'s net profit?

Kalaris Therapeutics, Inc. (KLRS) reported a net loss of $43.0M in its most recent fiscal year.

What is KLRS EV/EBITDA?

Kalaris Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -0.42. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
KLRS Overview KLRS Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.